On Wednesday, AbbVie Inc (NYSE:ABBV)’s shares inclined 2.19% to $63.80.
ABBV has market value of $103.34 billion while its EPS was booked as $1.71 in the last 12 months. The stock has 1.66 billion shares outstanding while 75.10% shares of the company were owned by institutional investors. In the profitability analysis, the company has gross profit margin of 80.70% while net profit margin was 9.90%.
The mean estimate for the short term price target for AbbVie Inc (NYSE:ABBV) stands at $75.43 according to 14 Analysts. The higher price target estimate for the stock has been calculated at $85.00 while the lower price target estimate is at $56.00.
Analysts mean recommendation for the stock is 2.10. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases.
Aetna Inc (NYSE:AET)’s shares dropped -2.73% to $108.76.
AET is currently valued at $39.02 billion. The company has 348.70 million shares outstanding and 90.50% shares of the company were owned by institutional investors. The company has 0.63 value in price to sale ratio while price to book ratio was recorded as 2.39. The company exchanged hands with 4.67 million shares as compared to its average daily volume of 3.41 million shares. It beta stands at 0.73.
The mean estimate for the short term price target for Aetna Inc (NYSE:AET) stands at $142.19 according to 16 Analysts. The higher price target estimate for the stock has been calculated at $160.00 while the lower price target estimate is at $134.00.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Aetna Inc. is a diversified health care benefits company. The Company offers a range of traditional, voluntary and consumer-directed health insurance products and related services.
At the end of Wednesday’s trade, Grifols SA, Barcelona (NASDAQ:GRFS)‘s shares surged 0.68% to $35.58.
GRFS has beta value of 1.00. The company has the market capitalization of $4.62 billion. ATR value of company was 0.72 while stock volatility for week was 1.64% while for month was 1.96%.
The mean estimate for the short term price target for Grifols SA, Barcelona (NASDAQ:GRFS) stands at $36.50 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $38.00 while the lower price target estimate is at $35.00.
Analysts mean recommendation for the stock is 2.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.